Chronic heart failure – modification of treatment paradigm

Abstract

The relevance of chronic heart failure (CHF) remains high. Despite significant advances in basic therapy for CHF patients, the prognosis remains poor. The prescription of inhibitors of sodium-glucose cotransporter type 2 dapagliflozin made it possible to change the paradigm of treatment of patients with CHF with low left ventricular ejection fraction.

Keywords

• chronic heart failure
• dapagliflozin
• inhibitors of sodium-glucose cotransporter type 2